If approved, where would neoadjuvant intralesional Daromun fit within the evolving treatment algorithm for patients with resectable locally advanced melanoma?
What barriers would you anticipate in implementing this approach?
Koehler et al. DOI: 10.1200/JCO.2026.44.17_suppl.LBA951